Shots:

• Beam to receive $300M up front & ~$1.35B in milestone along with royalties on net sales for the licensed program. The companies will share profits, development & commercialization costs in a 65%:35% ratio
• The collaboration combines Pfizer’s expertise in drug development with Beam’s leadership in base editing & mRNA/LNP technologies to advance gene-editing therapies for rare diseases
• Beam gets the right into a co-development & co-commercialization agreement for 1 program & will lead the research activities for 3 undisclosed targets. Pfizer exercises its opt-in license rights for all 3 targets & will lead the development activities, regulatory approvals, and commercialization for each product

Ref: Pfizer | Image: The Wall Street Journal